Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study

Deedwania, Prakash; Barter, Philip J.; Carmena, Rafael; Fruchart, Jean Charles; Grundy, Scott M.; Haffner, Steven; Kastelein, John J.P.; LaRosa, John C.; Schachner, Holly C.; Shepherd, James; Waters, David D.

doi:10.1016/s0140-6736(06)69292-1

Cited by 344 publications

(215 citation statements)

References 27 publications

Supporting

Mentioning

186

Contrasting

Unclassified

Order By: Relevance

“…We found similar values for blood pressure between the two groups, but lower HDL-C levels among male subjects, who also had a higher number of MetS components. Post hoc analysis of the Treating to New Targets (TNT) study (25) showed that, among inpatients with coronary heart disease, significantly more patients with MetS had a major cardiovascular event at a median follow-up of 4.9 years than patients without MetS.…”

Section: Discussionmentioning

confidence: 99%

Highly sensitive C-reactive protein and male gender are independently related to the severity of coronary disease in patients with metabolic syndrome and an acute coronary event

Monteiro

Pinheiro

Izar

et al. 2010

Braz J Med Biol Res

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Highly sensitive C-reactive protein and male gender are independently related to the severity of coronary disease in patients with metabolic syndrome and an acute coronary event

Monteiro

Pinheiro

Izar

et al. 2010

Braz J Med Biol Res

View full text Add to dashboard Cite

“…In parallel, it has been shown that patients with coronary artery disease and metabolic syndrome benefit from achieving lower low-density lipoproteincholesterol plasma levels compared to patients with coronary artery disease without metabolic syndrome. 30 The aim of this study is to quantify the risk of new vascular events associated with the metabolic syndrome and type II diabetes in patients with hypertension and manifest vascular disease.…”

Section: Introductionmentioning

confidence: 99%

Effect of metabolic syndrome or type II diabetes mellitus on the occurrence of recurrent vascular events in hypertensive patients

et al. 2008

View full text Add to dashboard Cite

Patients with hypertension and manifest vascular disease are at high risk for recurrent cardiovascular diseases. It is unknown if the metabolic syndrome further increases the risk in these patients. This study aims to quantify the effect of metabolic syndrome and type II diabetes on cardiovascular events in hypertensive patients with vascular disease. A total of 2196 hypertensive patients with vascular disease (cerebrovascular disease (34%), coronary heart disease (50%), peripheral arterial disease (28%), abdominal aortic aneurysm (13%)) from the Second Manifestations of Arterial Disease study were followed for up to 10 years (mean 3.9 years) for death, stroke and myocardial infarction. Age and sex adjusted hazard ratios (HR) were calculated for hypertensive patients with metabolic syndrome but without diabetes (n ¼ 775) and for hypertensive patients with type II diabetes (n ¼ 381), compared to merely hypertensive patients (n ¼ 1040).Forty-nine percent had metabolic syndrome (NCEP ATPIII definition) and 17% had type II diabetes. Metabolic syndrome predicted vascular death (HR 1.41, 95% confidence interval (CI) 1.01-1.98), stroke (HR 1.36, 95% CI 0.85-2.16) and myocardial infarction (HR 1.40, 95% CI 0.97-2.01). Type II diabetes accounted for even higher risks of vascular end points (HR 1.41-1.64). The effect of metabolic syndrome on future events could not be explained by the presence of type II diabetes. Even in high-risk patients with hypertension and vascular disease, presence of metabolic syndrome or type II diabetes identifies patients at high risk for future cardiovascular events. Identifying metabolic syndrome patients may direct therapy focusing on treatment of insulin resistance by reducing weight and increasing physical activity.

show abstract

“…The results of event trials indicated that treatment with lovastatin, pravastatin, fluvastatin, atorvas- tatin, simvastatin and rosuvastatin has beneficial effects on events 33,34,[36][37][38][39][40][41][43][44][45][46][47][48] (Table 5). The results of torcetrapib event trials were classified as harmful (harm), as the event trial showed increased risk of mortality and morbidity 35) .…”

Section: Congruency Between Results For Mean Common and Mean Maximum mentioning

confidence: 99%

“…Ultimately, this resulted in 15 CIMT trials for analyses 5, 7-10, 12, 13, 15, 16, 18,19,21,22,30,32) . For each drug used in the CIMT trials, the corresponding event trials were searched, resulting in 15 clinical event trials for lovastatin, pravastatin, fluvastatin, simvastatin, atorvastatin, torcetrapib, rosuvastatin and ezetimibe, as presented in Table 2 [33][34][35][36][37][38][39][40][41][42][43][44][45][46][47][48][49] .…”

Section: Search Strategymentioning

confidence: 99%

Mean Common or Mean Maximum Carotid Intima-Media Thickness as Primary Outcome in Lipid-Modifying Intervention Studies

Doğan

Kastelein

Grobbee

et al. 2011

JAT

View full text Add to dashboard Cite

Aim: Carotid intima-media thickness (CIMT) measurements are used as a disease outcome in randomized controlled trials that assess the effects of lipid-modifying treatment. It is unclear whether common CIMT or mean maximum CIMT should be used as the primary outcome. We directly compared both measurements using aspects that are of great importance in deciding which is most favorable for use in clinical trials.

show abstract

Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study

Cited by 344 publications

References 27 publications

Highly sensitive C-reactive protein and male gender are independently related to the severity of coronary disease in patients with metabolic syndrome and an acute coronary event

Highly sensitive C-reactive protein and male gender are independently related to the severity of coronary disease in patients with metabolic syndrome and an acute coronary event

Effect of metabolic syndrome or type II diabetes mellitus on the occurrence of recurrent vascular events in hypertensive patients

Mean Common or Mean Maximum Carotid Intima-Media Thickness as Primary Outcome in Lipid-Modifying Intervention Studies

Contact Info

Product

Resources

About